Clinical Trial: Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HZ-V055 in Participants with RAS-Mutated Advanced Solid Tumors (China)

China, Aug. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HZ-V055 in Participants with RAS-Mutated Advanced Solid Tumors'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130745

Registration Time: 2026/08/24

Type: Interventional study

Primary Sponsor: Fudan University Shanghai Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338357

Published by HT Digital Content Services with permission from Health Daily Digest....